Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2003
04/03/2003WO2003027085A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003WO2003027083A1 Bicyclo[3,1,0]hexane containing oxazolidinone antibiotic and derivatives thereof
04/03/2003WO2003027081A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
04/03/2003WO2003027080A1 3-substituted-4-pyrimidone derivatives
04/03/2003WO2003027078A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003WO2003027077A1 Water-soluble phenylpyridazine derivatives and drugs containing the same
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027074A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003027068A2 Substituted amines for the treatment of neurological disorders
04/03/2003WO2003027065A1 3-desoxy-vitamin d3 analog esters
04/03/2003WO2003027061A2 Muscarinic agonists
04/03/2003WO2003027060A1 Diphenylbutane amide derivatives
04/03/2003WO2003027058A1 Sphingolipids
04/03/2003WO2003026744A1 The use of epothilones and analogs in conjunction with ophthalmic surgery
04/03/2003WO2003026743A2 Opioid formulations having reduced potential for abuse
04/03/2003WO2003026718A1 Coated implantable medical device
04/03/2003WO2003026714A1 Porous ceramic composite bone grafts
04/03/2003WO2003026710A1 Mixture for use as a protective dressing
04/03/2003WO2003026709A1 Liquid mixture for use as a dressing spray
04/03/2003WO2003026697A2 Organoleptically acceptable intraorally disintegrating compositions
04/03/2003WO2003026696A1 Method of controlling proliferation of cancer cells and cell death
04/03/2003WO2003026691A2 Use of hmgb1 for the activation of dendritic cells
04/03/2003WO2003026684A1 Modulation of physiological processes and agents useful for same
04/03/2003WO2003026680A2 Method and topical formulation for treating skin conditions associated with aging
04/03/2003WO2003026678A1 Novel pharmaceutical composition with improved defoaming activity
04/03/2003WO2003026677A1 Pharmaceutical composition comprising chito-oligomers
04/03/2003WO2003026676A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
04/03/2003WO2003026675A1 Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
04/03/2003WO2003026674A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
04/03/2003WO2003026673A1 Modulation of vitamin storage
04/03/2003WO2003026672A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
04/03/2003WO2003026671A1 Method of treating middle ear infections
04/03/2003WO2003026670A2 Method for inhibiting the proliferation of hepatic stellate cells with a ligand of the low affinity glucocorticoid binding site (lags)
04/03/2003WO2003026669A1 Monobactam antibacterial compounds and methods of use thereof
04/03/2003WO2003026668A1 Ophthalmologic treatment methods using selective inos inhibitors
04/03/2003WO2003026667A1 Quinazolino- and quinolino- guanidines as ligands for the neurop eptide ff (npff) receptors
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026662A1 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
04/03/2003WO2003026661A1 Insulin secretion accelerator and novel pyrimidine derivative
04/03/2003WO2003026660A1 An enantiomerically pure diarylmethylpiperazine and methods of using same
04/03/2003WO2003026659A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003WO2003026658A1 Method for the treatment or prevention of atopic dermatitis
04/03/2003WO2003026657A1 Compounds for the treatment of pain
04/03/2003WO2003026656A1 New formulations and use thereof
04/03/2003WO2003026655A1 New formulations and use thereof
04/03/2003WO2003026654A1 Nicotine-containing film preparation
04/03/2003WO2003026653A1 Pharmaceutical composition comprising metformin and n-`2-hydroxy-3-(1-piperidinyl)-propoxy! pyridine-1-oxide-3-carboximidoyl chloride
04/03/2003WO2003026652A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
04/03/2003WO2003026651A1 Method of inhibiting the production and/or effects of intestinal pro-inflammatory cytokines, prostaglandins and others
04/03/2003WO2003026649A1 Methods of increasing endogenous testosterone levels
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026646A1 Photodynamic porphyrin antimicrobial agents
04/03/2003WO2003026644A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
04/03/2003WO2003026643A2 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
04/03/2003WO2003026642A1 Freeze-dried pharmaceutical preparation
04/03/2003WO2003026641A2 Modulation of stat activity
04/03/2003WO2003026640A1 Treating food allergies and/or food intolerances
04/03/2003WO2003026638A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003WO2003026637A2 Dosage form for treatment of diabetes mellitus
04/03/2003WO2003026636A1 Thrombus/thrombogenesis inhibitors
04/03/2003WO2003026635A2 Improved method of treating the syndrome of type 2 diabetes in humans
04/03/2003WO2003026634A1 Amines with antialcoholic agents
04/03/2003WO2003026633A1 Natural pharmaceutical composition against parasitosis in bees
04/03/2003WO2003026632A2 Substituted phenol compounds useful for anesthesia and sedation
04/03/2003WO2003026631A1 Delivery of drug esters through an inhalation route
04/03/2003WO2003026630A1 Dosage forms having an inner core and outer shell with different shapes
04/03/2003WO2003026629A2 Modified release dosage forms
04/03/2003WO2003026628A2 Composite dosage forms having an inlaid portion
04/03/2003WO2003026627A1 Composite dosage forms
04/03/2003WO2003026626A2 Modified release dosage forms
04/03/2003WO2003026625A1 Modified release dosage forms
04/03/2003WO2003026624A1 Modified release dosage forms
04/03/2003WO2003026623A1 Intraorally disintegrating valdecoxib compositions
04/03/2003WO2003026619A1 Granules having improved dosing properties
04/03/2003WO2003026617A2 (ester)-lysolecithins in liposomes
04/03/2003WO2003026616A1 Edible composition and dosage form comprising an edible shell
04/03/2003WO2003026615A2 Modified release dosage forms
04/03/2003WO2003026614A1 Dosage form containing a confectionery composition
04/03/2003WO2003026613A1 Fondant-based pharmaceutical composition
04/03/2003WO2003026612A2 Dosage forms having an inner core and outer shell
04/03/2003WO2003026611A2 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
04/03/2003WO2003026610A2 Process for the preparation of fast dissolving dosage form
04/03/2003WO2003026608A1 Topical compositions containing fluid-absorbent solids and adhesive fluids
04/03/2003WO2003026601A1 Oral composition for treating sensitive teeth
04/03/2003WO2003026591A2 Modification of feeding behavior
04/03/2003WO2003026589A2 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
04/03/2003WO2003026585A2 Compositions and methods for inhibiting eccrine perspiration in humans
04/03/2003WO2003026584A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
04/03/2003WO2003026581A2 Pharmaceutical compositions and methods for treating cancer
04/03/2003WO2003026576A2 Induction of brown adipocytes by transcription factor nfe2l2
04/03/2003WO2003026574A2 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
04/03/2003WO2003026573A2 Screening and selection methods for statin drug combinations
04/03/2003WO2003026572A2 Crystalline forms of ertapenem sodium
04/03/2003WO2003026570A2 Reduced toxicity cisplatin formulations and methods for using the same
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026567A2 Use of neuraminidase inhibitors to prevent flu associated bacterial infections
04/03/2003WO2003026565A2 Composition and treatment method for brain and spinal cord injuries
1 ... 5512 5513 5514 5515 5516 5517 5518 5519 5520 5521 5522 5523 5524 5525 5526 5527 5528 5529 5530 5531 5532 ... 7860